drug

semaglutide

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about semaglutide: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

155Connections

0Hypotheses

1Analyses

50Outgoing

48Incoming

0Experiments

Summary

semaglutide is a therapeutic compound targeting neurodegeneration research. Key relationships include: treats, associated with, causes. Associated with Alzheimer's disease, Type 2 Diabetes Mellitus, acute kidney injury. Connected to 10 entities in the SciDEX knowledge graph.

View on Wiki →

💊 Drug Info

Name	semaglutide
Key Genes/Proteins	SIRT1, AMPK
Related Diseases	Type 2 Diabetes Mellitus, polycystic ovary syndrome, acute pancreatitis, medullary thyroid carcinoma, acute kidney injury
Related Pathways	inflammation

Wiki Pages (20)

Knowledge base pages for this entity

Pathway Diagram

graph TD
    semaglutide["<b>semaglutide</b>"]
    Type_2_Diabetes_Mellitus{"Type 2 Diabetes Mellitus"}
    semaglutide -->|"treats"| Type_2_Diabetes_Mellitus
    glycemic_control(["glycemic control"])
    semaglutide -->|"regulates"| glycemic_control
    Alzheimer_s_disease{"Alzheimer's disease"}
    semaglutide -->|"treats"| Alzheimer_s_disease
    neuroinflammation(["neuroinflammation"])
    semaglutide -->|"inhibits"| neuroinflammation
    polycystic_ovary_syndrome{"polycystic ovary syndrome"}
    semaglutide -->|"treats"| polycystic_ovary_syndrome
    acute_pancreatitis{"acute pancreatitis"}
    semaglutide -->|"causes"| acute_pancreatitis
    medullary_thyroid_carcinoma{"medullary thyroid carcinoma"}
    semaglutide -->|"associated with"| medullary_thyroid_carcinoma
    acute_kidney_injury{"acute kidney injury"}
    semaglutide -->|"causes"| acute_kidney_injury
    medullary_thyroid_carcinoma -->|"associated with"| semaglutide
    multiple_endocrine_neoplasia_syndrome_ty{"multiple endocrine neoplasia syndrome type 2"}
    multiple_endocrine_neoplasia_syndrome_ty -->|"associated with"| semaglutide
    style semaglutide fill:#1a3a4a,stroke:#4fc3f7,stroke-width:3px,color:#e0e0e0

Outgoing (107)

Target	Relation	Type	Str
GFAP	inhibits	protein	0.95
Polycystic Ovary Syndrome	treats	disease	0.95
PCOS	treats	disease	0.95
amyloid plaque deposition	prevents	process	0.93
cognitive capability	promotes	phenotype	0.92
AMPK/SIRT1/NF-κB Signaling Pathway	activates	pathway	0.92
Hypoxia/Reoxygenation-Induced Cardiomyocyte Injury	protects_against	disease	0.92
Alzheimer's disease	therapeutic_target	disease	0.91
OXT	activates	protein	0.90
Ampk/Sirt1/Nf-Κb Signaling Pathway	activates	pathway	0.90
Autophagy	upregulates	process	0.88
STAR	downregulates	protein	0.85
Testosterone	downregulates	compound	0.85
PI3K	activates	pathway	0.80
AKT	activates	protein	0.80
MTOR	activates	protein	0.80
TLR4	inhibits	protein	0.80
cognitive function	enhances	phenotype	0.80
OBESITY	treats	disease	0.80
Insulin Resistance	treats	phenotype	0.80
NF-κB	inhibits	protein	0.80
microglia	inhibits_overactivation	cell_type	0.80
astrocytes	inhibits_overactivation	cell_type	0.80
Type 2 Diabetes Mellitus	treats	disease	0.70
glycemic control	regulates	process	0.70
neuroinflammation	inhibits	process	0.70
polycystic ovary syndrome	treats	disease	0.70
acute pancreatitis	causes	disease	0.70
medullary thyroid carcinoma	associated_with	disease	0.70
acute kidney injury	causes	disease	0.70
TAU	treats	protein	0.70
Alzheimer's disease	treats	disease	0.70
APP	inhibits	gene	0.65
APP	activates	gene	0.65
INFLAMMATION	treats	phenotype	0.65
COGNITIVE DECLINE	treats	phenotype	0.65
CYTOKINES	phosphorylates	phenotype	0.65
CYTOKINES	activates	phenotype	0.65
FIBROSIS	inhibits	disease	0.65
AMYLOID	regulates	protein	0.65
AMPK	activates	gene	0.65
OXIDATIVE STRESS	treats	phenotype	0.65
INFLAMMATION	inhibits	phenotype	0.65
DEMENTIA	interacts_with	disease	0.65
NEURONS	protects_against	cell_type	0.65
NEURONS	activates	cell_type	0.65
NEUROINFLAMMATION	treats	phenotype	0.65
OXIDATIVE STRESS	inhibits	phenotype	0.65
ALZHEIMER'S DISEASE	protects_against	disease	0.65
AMYLOID	degrades	protein	0.65

Incoming (48)

Source	Relation	Type	Str
medullary thyroid carcinoma	associated_with	disease	0.70
multiple endocrine neoplasia syndrome type 2	associated_with	disease	0.70
GFAP	suppressed_by	protein	0.70
TAU	protects_against	protein	0.70
SYNAPTIC PLASTICITY	activates	phenotype	0.65
NEURON	inhibits	cell_type	0.50
DIABETES	inhibits	disease	0.50
NEURODEGENERATION	associated_with	phenotype	0.50
NEUROINFLAMMATION	associated_with	phenotype	0.50
COGNITIVE DECLINE	associated_with	phenotype	0.50
LIRAGLUTIDE	associated_with	drug	0.45
DAPAGLIFLOZIN	associated_with	drug	0.45
INFLAMMATION	associated_with	phenotype	0.45
OXIDATIVE STRESS	associated_with	phenotype	0.45
SYNAPTIC PLASTICITY	associated_with	phenotype	0.45
DENTATE GYRUS	associated_with	brain_region	0.45
ASTROGLIOSIS	associated_with	phenotype	0.45
PARKINSON'S DISEASE	associated_with	disease	0.45
MICROGLIAL ACTIVATION	associated_with	phenotype	0.45
MINOCYCLINE	associated_with	drug	0.45
ALZHEIMER'S DISEASE	associated_with	disease	0.45
NLRP3 INFLAMMASOME	associated_with	pathway	0.45
PI3K/AKT PATHWAY	associated_with	pathway	0.45
LIRAGLUTIDE	metabolizes	drug	0.35
EXENATIDE	therapeutic_target	drug	0.35
RHEUMATOID ARTHRITIS	therapeutic_target	disease	0.35
RHEUMATOID ARTHRITIS	protects_against	disease	0.35
BRAINSTEM	inhibits	brain_region	0.35
BRAINSTEM	regulates	brain_region	0.35
NEUROINFLAMMATION	implicated_in	process	0.35
DEMENTIA	inhibits	disease	0.35
RAS	inhibits	gene	0.35
OBESITY	inhibits	disease	0.35
NEURODEGENERATION	regulates	process	0.35
DIABETES	regulates	disease	0.35
RAS	therapeutic_target	gene	0.35
PARKINSON'S DISEASE	therapeutic_target	disease	0.35
DOPAMINERGIC NEURONS	inhibits	cell_type	0.35
INFLAMMATION	protects_against	process	0.35
AMPK	protects_against	gene	0.35
INSULIN RESISTANCE	associated_with	process	0.35
NF-KB	protects_against	gene	0.35
HEART FAILURE	regulates	disease	0.35
FIBROBLASTS	regulates	cell_type	0.35
ALZHEIMER'S DISEASE	activates	disease	0.35
ASTROCYTES	activates	cell_type	0.35
AMYLOID	activates	protein	0.35
ALZHEIMER'S DISEASE	expressed_in	disease	0.35

Targeting Hypotheses (0)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
No targeting hypotheses

Mentioning Analyses (1)

Scientific analyses that reference this entity

What are the molecular mechanisms by which GLP-1RAs provide neuroprotective effe

neurodegeneration | 2026-04-14 | 0 hypotheses

Experiments (0)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
No experiments found

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
No papers found

semaglutide

Understanding Entity Pages

Summary

Wiki Pages (20)

cbs-psp-daily-action-plan

Personalized Treatment Plan — Atypical Parkinsonism (CBS/PSP)

Therapeutics

Alzheimer's Disease

PD Cure Roadmap

Clinical Trials Dashboard

Neuroprotection Strategies in Neurodegeneration

Insulin Signaling in Parkinson's Disease

Experiment Prioritization Index — Neurodegeneration

university-michigan

Gut-Brain Axis in Neurodegeneration

glp1-receptor-agonists

Mitochondria in Neurodegeneration

AD Therapeutic Approaches Ranked Scorecard

Microglia Activation Mechanism

NIH Drug Repurposing Program for Neurodegenerative Diseases

potassium-channel-openers-parkinsons

Biomarker-Therapeutic Development Nexus

AD Combination Therapy Matrix

GLP-1 Signaling Pathway in Neurodegeneration